Biomedical benefits of cannabinoids?

Addiction Biology

Volumn 4, Issue 2, 1999, Pages 111-126

  Ashton, C H ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APPETITE STIMULANT; CANNABINOID; DOMPERIDONE; DRONABINOL; LEVONANTRADOL; METOCLOPRAMIDE; NABILONE; PHENOTHIAZINE; SEROTONIN 3 ANTAGONIST; SPASMOLYTIC AGENT;

ANOREXIA; ASTHMA; ATAXIA; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DEPERSONALIZATION; DROWSINESS; DRUG DEPENDENCE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TOLERANCE; DYSPHORIA; EPILEPSY; EUPHORIA; GLAUCOMA; HEADACHE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SEDATION; SPASTICITY; TACHYCARDIA; VOMITING; XEROSTOMIA;

EID: 0032938231     PISSN: 13556215     EISSN: None     Source Type: Journal    
DOI: 10.1080/13556219971623     Document Type: Review

References (128)

1. Mechoulam R. The pharmacohistory of cannabis sativa. In: Mechoulam R, editor. Cannabinoids as therapeutic agents. Boca Raton: CRC Press; 1986, pp. 1-19.
2. Brecher EM. Licit and illicit drugs. New York: Consensus Union, Mount Vernon; 1972.
3. Grinspoon L, Bakalar JB. Marihuana, the forbidden medicine. New Haven and London: Yale University Press; 1993.
4. O'Shaugnessy WB. (1843) On the cannabis indica or Indian hemp. Pharmacol J 1843;2:594.
5. British Medical Association. Therapeutic uses of cannabis. The Netherlands: Harwood Academic Publishers; 1997.
6. Robson P. Therapeutic aspects of cannabis and cannabinoids. London: Department of Health; 1998.
7. Ashton CH. Cannabis: clinical and pharmacological aspects. London: Department of Health; 1998.
8. Evans F. The separation of central from peripheral effects on a structural basis. Planta Med 1991;57: 560-67.
9. Devane WA, Dysarz WA, Johnson MR, Melvin LS, Howlett AC. Determination and characterisation of a cannabinoid receptor in rat brain. Mol Pharmacol 1988;34:605.
10. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of cannabinoid receptor and functional expression of the cloned DNA. Nature 1990;346:561.
11. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of peripheral receptor for cannabinoids. Nature 1993;365:61-5.
12. Musty RE, Reggio P, Consroe P. A review of recent advances in cannabinoid research and the 1994 international symposium on cannabis and the cannabinoids. Life Sci 1995;56:1933-40.
13. Devane WA, Hanus L, Breuer A. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-9.
14. Pertwee RG. Pharmacological, physiological and clinical implications of the discovery of cannabinoid receptors: an overview. In: Pertwee RG, editor. Cannabinoid receptors. London: Academic Press; 1995, pp. 1-34.
15. Doyle E, Spence AA. Cannabis as a medicine? Br J Anaesth 1995;74:359-61.
16. Robson P. Cannabis. Arch Dis Child 1997;77: 164-6.
17. Voth EA, Schwartz RH. Medical applications of delta-9-tetrahydrocannabinol and marijuana. Ann Intern Med 1997;126:791-8.
18. Dalzell AM, Bartlett H, Lilleyman JS. Nabilone: an alternative antiemetic for cancer chemotherapy. Arch Dis Child 1986;B9:1314-19.
19. British National Formulary, 1998;35:192-3
20. Cocchetto DM, Cook LF, Cato AE. A critical review of the safety and antiemetic efficacy of delta-9-tetrahydrocannabinol. Drug Intell Clin Pharm 1981;15:867-75.
21. Vincent BJ, McQuiston DJ, Einhorn LH, Nagyu CM, Brames M. Review of cannabinoids and their antiemetic effectiveness. Drugs 1983; 25 (Suppl. 1):52-62.
22. Levitt M. Cannabinoids as antiemetics in cancer chemotherapy. In: Mechoulam R, editor. Cannabinoids as therapeutic agents. Boca Raton: CRC Press; 1986, pp. 71-83.
23. Formukong EA, Evans AT, Evans FJ. The medicinal uses of cannabis and its constituents. Phytother Res 1989;3:219-31.
24. Wada JK, Bogdon DL, Gunnell JC, Hum GJ, Gota CH, Rieth TE. Double-blind randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy. Cancer Treat Rev 1982;9 (Suppl. B):39-44.
25. Jones SE, Durant JR, Greco FA, Robertone A. A multi-institutional phase III study of nabilone vs. placebo in chemotherapy-induced nausea and vomiting. Cancer Treat Rev 1982;9:45S-48S.
26. Sallan S, Zinberg N, Frel E III. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 1975;293:795-7.
27. Chang AE, Shiling DJ, Stillman RC, et al. Delta-9-THC as an antiemetic in cancer patients receiving high-dose methotrexate. Ann of Intern Med I979;91:819-30.
28. Nagy CM, Furnas BE, Einhorn LH, Bond WH. Nabilone: antiemetic crossover study in cancer chemotherapy patients. Proc Am Soc Cancer Res 1985;19:30.
29. Herman TS, Einhorn LH, Jones SE, et al. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 1979;300:1295-7.
30. Einhorn LH, Nagy C, Furnas B, Williams SD. Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharm 1981;21:64S-69S.
31. Niiranan A, Mattson K. A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol 1985;8:336-40.
32. Nierderle N, Schutte J, Schmidt CG. Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonscminomatous testicular cancer receiving cisplatin therapy. Klin Wochenschr 1986;64:362-5.
33. Pomeroy M, Fennelly JJ, Towers M. Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemother Pharmacol 1986;17:285-8.
34. Chan HSL, Correia JA, MacLeod SM. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics 1987;79:946-52.
35. Orr LE, McKernan JF. Antiemetic effect of delta-9-THC in chemotherapy-associated nausea and emesis as compared to placebo and compazine. J Clin Pharmacol 1981;21:76S-80S.
36. 9-THC for refractory vomiting induced by cancer chemotherapy. J Am Med Assoc 1980;243:1241-3.
37. Johansson R, Kilkku P, Groenroos M. A double-blind, controlled trial of nabilone vs. prochlorperazinc for refractory emesis induced by cancer chemotherapy. Cancer Treat Rev 1982; 9 (Suppl. B):25-33.
38. Ahmedzai S, Carlyle DL, Calder IT, Moran F. Antiemetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer 1983;48:657-63.
39. Frytak S, Moertel CG, O'Fallon JR, (1979) Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Intern Med 1979;91:825-30.
40. Niedhart J, Gagen M, Wilson H, Young D. Comparative trial of antiemetic effects of THC and haloperidol. J Clin Pharmacol 1981;21: 38S.
41. Ungerleider JT, AndyrsiakT, Fairbanks L, Goodnight J, Sarna G, Jamison K. Cannabis and cancer chemotherapy. A comparison of oral delta-9-THC and prochlorperazine. Cancer 1982;50:636-45.
42. Lane M, Vogel CL, Ferguson J. Dronabinol and prochlorperazine in combination are better than either agent alone for treatment of chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol 1991;8:326.
43. Chang AE, Shiling DJ, Stillman RC, et al. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 1981;47:1746-51.
44. Gralla RJ, Tyson LB, Clark RA, Bordin LA, Kelsen DP, Kaiman LB. Antiemetic trials with high dose metoclopramide: superiority over THC, and preservation of efficacy in subsequent chemotherapy course. Proc ASCO 1982; C-222.
45. Sheidler VR, Ettinger DS, Diasio RB, Enterline JP, Brown MD. Double-blind multiple-dose crossover study of the antiemetic effect of intramuscular levonantradol compared to prochlorperazine. J Clin Pharmacol 1984;24:155-9.
46. Lucraft HH, Palmer MK. Randomised clinical trial of levonantradol and chlorpromazine in the prevention of radiotherapy-induced vomiting. Clin Radiol 1982;33:621-2.
47. Abrahamov A, Abrahamov A, Mechoulam R. An efficient new cannabinboid antiemetic in pediatric oncology. Life Sci 1995;56:2097-102.
48. Cunningham D, Bradley CJ, Forrest GJ, et al. A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexmethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Cancer Clin Oncol 1988;24: 685-9.
49. Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG. Recent clinical experience with dronabinol. Pharmacol Biochem Behav 1991;40:695-700.
50. Vinciguerra V, Moore T, Brennan E. Inhalation marijuana as an antiemetic for cancer chemotherapy. NY State J Med 1988;88:525-7.
51. Doblin RE, Kleiman AR. Marijuana as antiemetic medicine: a survey of oncologists' experiences and attitudes. J Clin Oncol 1991;9:1314-9.
52. Hodges C. I wish I could get it at the chemist's. Independent 1993; 23 February.
53. Davies C. Drug dealers saved my wife from her MS hell. Mail on Sunday 1992; 15 November.
54. Doyle C. (1992) High, dry and happier. Daily Telegraph 1992;24:November.
55. Ferriman A. Marihuana: the best medicine? The Times 1993; 4 May.
56. Handscombe M. Cannabis: why doctors want it to be legal. Independent 1993; 23 February.
57. James T. Breaking the law to beat MS. Yorkshire Post 1993; 27 September.
58. Meinck HM, Schonle PW, Conrad B. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 1989;236:120-122.
59. Consroe P, Sandyk R. Potential role of cannabinoids for therapy of neurological disorders. In: Murphy L, Bartke, A, editors. Marijuana/cannabinoids. Neurobiology and neurophysiology. Boca Raton: CRC Press; 1992, pp. 459-24.
60. Consroe P, Sandyk R, Snider SR. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 1996;30:277-82C.
61. Petro DJ, Ellenberger C. Treatment of human spasticity with delta-9-tetrahydrocannabinol. J Clin Pharmacol 1981;21:413S-16S.
62. Clifford DB. THC for tremor in multiple sclerosis. Ann Neurol 1983; 13:669-71.
63. Ungerleider T, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Substance Abuse 1988;7:39-50.
64. Martyn CN, Illis LS, Thorn J. Nabilone in the treatment of multiple sclerosis. Lancet 1995;345: 579.
65. Greenberg HS, Werness SAS, Pugh JE, Andrus RO, Anderson DJ, Domino EF. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther 1994;55:324-8.
66. Dunn M, Davies R. The perceived effects of marijuana on spinal cord injured males. Paraplegia 1974;12:175.
67. Malec J, Harvey RF, Cayner JJ. Cannabis effects on spasticity in spinal cord injury. Arch Phys Med Rehab 1982;63:116-18.
68. Petro DJ. Marihuana as a therapeutic agent for muscle spasm or spasticity. Psychosomatics 1980; 21:81-5.
69. Maurer M, Henn V, Dittrich A, Hoffman A. Delta-9-THC shows antispastic and analgesic effects in a single case double blind trial. Eur Arch Psychiatr Clin Neurosci 1990;240:1-4.
70. Frankel JP, Hughes A, Lees AJ, Stern GM. Marijuana for Parkinsonian tremor. J Neurol Neurosurg Psychiatr 1990;53:436.
71. Consroe P, Sandyk R, Snider SR. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 1986;30:277-82C.
72. Consroe P, Laguna J, Allender J, et al. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav 1991;40:701-8.
73. Segal M. Cannabinoids and analgesia. In: Mechoulam R, editor. Cannabinoids as therapeutic agents. CRC Press: Boca Raton, Florida; 1986, pp. 105-20.
74. Noyes R, Brunk SF, Baram DA, Canter A. analgesic effect of delta-9-THC. J Clin Pharmacol 1975;15:139-43.
75. Noyes R, Brunk SF, Avery DH, Canter A. The analgesic properties of delta-9-THC and codeine. Clin Pharmacol Ther 1975; 18:84-9.
76. Jain AK, Ryan JR, McMahon FG, Smith G. Evaluation of intramuscular levonatradol and placebo in acute postoperative pain. J Clin Pharmacol 1981;21:320S-26S.
77. Finnegan-Ling D, Musty RE. Marinol and phantom limb pain: a case study. Proc Int Cannabis Res Soc 1994:53.
78. Raft D, Gregg J, Ghia J, Harris L. Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response. Clin Pharmacol Ther 1977;21:26-33.
79. Lindstrom P, Lindblom U, Boreus L. Lack of effect of cannabidiol in sustained neuropathia. Paper presented at Marijuana 1987 International Conference on Cannabis, Melbourne, 2-4 September 1987 (cited by Consroe & Sandyk, 1992, (59).
80. Paton WDM, Pertwee RG. The actions of cannabis in man. In: Nahas GG, Paton WDM, editors. Marijuana: chemistry, pharmacology, metabolism and clinical effects. Oxford: Pergamon Press; 1973, pp. 735-8.
81. Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995; 10:89-97.
82. Hall W, Solowij N, Lemon J, editors. The health and psychological consequences of cannabis use. National Drug Strategy Monograph Series No. 25. Canberra: Australian Government Publishing Service, 1994.
83. Gross H, Eben MH, Faden VB et al. A double-blind trial of delta-9-THC in primary anorexia nervosa. J Clin Psychopharmacol 1983;3: 165-71.
84. Consroe P, Snider SR. Therapeutic potential of cannabinoids in neurological disorders. In: Mechoulam R, editor. Cannabinoids as therapeutic agents. CRC Press: Boca Raton, Florida 1986, pp. 21-49.
85. Pertwee RG. The central neuropharmacology of psychotropic cannabinoids. In Balfour DJK, editor. Psychotropic drugs of abuse. New York: Pergamon Press; 1990, pp. 355-429.
86. Cunha JM, Carlini EA, Pereira AE, Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980; 21:175-85.
87. Ames FR, Cridland S. Anticonvulsant effect of cannabidiol. S African Med J 1986;69:14.
88. Trembly B, Sherman M. Double-blind clinical study of cannabidiol as a secondary anticonvulsant. Paper presented at Marijuana 1990 International Conference on Cannabis and Cannabinoids, Kolympari (Crete), 8-11 July 1990 (cited by Consroe & Sandyk, 1992, (54).
89. Keeler MH, Reifler CB. Grand mal convulsions subsequent to marihuana use. Dis Nerv Syst 1967;18:474-5.
90. Consroe PF, Wood GC, Buchsbaum H. Anti-convulsant nature of marihuana smoking. JAMA 1975;234:306-7.
91. Ellison JM, Gelwan E, Ogletree J. Complex partial seizure symptoms affected by marijuana abuse. J Clin Psychiatr 1990;51:439-40.
92. Hepler RS, Frank IM. Marihuana smoking and intraocular pressure. JAMA 1971;217:1392.
93. Hepler RS, Frank IM, Petrus R. Ocular effects of marihuana smoking. In: Braude MC, Szara S, editors. The pharmacology of marihuana. New Youk: Raven Press; 1976, pp. 829-24
94. Perez-Reyes M, Wagner D, Wall ME, Davis KH. Intravenous administration of cannabinoids and intraocular pressure. In: Braude MC, Szara S, editors. The pharmacology of marihuana. New York: Raven Press; 1976, pp. 829-32.
95. Cooler P, Gregg JM. Effect of delta-9-tetra-hydrocannabinol on intraocular pressure in humans. Southern Med J 1977;70:951-4.
96. Jones RT, Benowitz N, Herning RI. Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol 1981;21:143S-52S.
97. Merritt JC, Crawford WJ, Alexander PC, Anduze AL, Gelbart SS. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology 1980;87:222-8.
98. Merritt JC, Olsen JL, Armstrong JR, McKinnon SM. Topical delta-9-THC in hypertensive glaucomas. J Pharm Pharmacol 1981;33:40-1.
99. Jones RT, Benowitz N, Bachman J. Clinical studies of cannabis tolerance and dependence, In: Dornbush RL, Freedman AM, Fink M, editors. Chronic cannabis use. New York: New York Academy of Sciences; 1976, pp. 221-39.
100. 9-tetrahydrocannabinol in man. Arch Ophthalmol 1982;100:265-7.
101. 9-tetrahydrocannabinol in human eyes. Arch Ophthalmol 1983;101:591-4.
102. Adler MW, Geller EB. Ocular effects of cannabinoids as therapeutic agents. In: Mechoulam R, editor. Cannabinoids as therapeutic agents. Boca Raton: CRC Press; 1986, pp. 51-70.
103. Roffman RA. Marijuana as medicine. Seattle: Madrona Publishers; 1982.
104. Razdan RK, Howes JF, Pars HG. Development of orally active cannabinoids for the treatment of glaucoma. In: Harris LS, editor. Problems of drug dependence Nida Research Monograph 43. Washington DC: Department of Health and Human Services; pp. 157-63.
105. Hollister LE. Health aspects of cannabis. Pharmacol Rev 1986;38:1-20.
106. Graham JDP. The bronchodilator action of cannabinoids. In: Mechoulam R, editor. Cannabinoids as therapeutic agents. Boca Raton: CRC Press; 1986; pp. 147-158.
107. Tashkin DP, Shapiro BJ, Frank IM. Acute effects of marihuana on airway dynamics in spontaneous and experimentally produced bronchial asthma. In: Braude MC, Szara S, editors. The pharmacology of marihuana. New York: Raven Press; 1976, 785-93.
108. 9-tetrahydrocannabinol in healthy and asthmatic subjects. Am Rev Res Dis 1977;115: 57-65.
109. Vachon L, Mikus P, Morrisey W, Fitzgerald M, Gaenser E. Bronchial effects of marihuana smoke in asthma. In: Braude MC, Szara S, editors. The pharmacology of marihuana. New York: Raven Press; 1976, pp. 777-84.
110. Williams SJ, Hartley JPR, Graham JDP. Bronchodilator effect of delta-9-THC administered by aerosol to asthmatic patients. Thorax 1976;31: 720-3.
111. Archer RA, Stark P, Lemberger L. Nabilone. In: Mechoulam R, editor. Cannabinoids as therapeutic agents. Boca Raton: CRC Press; 1986, pp. 85-103.
112. Benewitz NL, Jones RT. Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. J Clin Pharmacol 1981;21:214-23S.
113. Fabre LF, McIendon D. The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. J Clin Pharmacol 1981;21: 377-82S.
114. Ilaria RL, Thornby JI, Fann WE. Nabilone, a cannabinol derivative, in the treatment of anxiety neurosis. CurrTher Res 1981;29:943-9.
115. Carlini EA, Cunha JM. Hypnotic and anti-epileptic effects of cannabidiol. J Clin Pharmacol 1981;21:417-27S.
116. Regelson W, Butler JR, Schulz J, et al. Delta-9-THC as an effective antideprcssant and appetite-stimulating agent in advanced cancer patients. In: Braude MC, Szara S, editors. The pharmacology of marihuana. New York: Raven Press; 1976, pp. 763-76.
117. Chesher GB Jackson DM. The quasi-morphine withdrawal syndrome: effect of cannabinol, cannabidiol and tetrahydrocannabinol. Pharmacol Biochem Behav 1985;23:13-15.
118. Nahas GG. The medical use of cannabis. In: Richter RW, editor. Marihuana in science and medicine. New York: Raven Press; 1984, pp. 247-61.
119. Maykut MO. Health consequences of acute and chronic marihuana use. Prog Neuro-Psychopharmacol Biol Psychiatr 1985;9:209-38.
120. Hollister LE. Cannabis - 1988. Acta Psych Scand 1985;78 (Suppl. 345):108-18.
121. Johns A. Psychiatric aspects of cannabis use. London: Department of Health; 1998.
122. Twycross RG, McQuay HJ. Opioids. In: Wall PD, Melzack R, editors. Textbook of pain, 2nd edn. London: Churchill Livingston; 1989, pp. 686-701.
123. Benson M, Bentley AM. Lung disease induced by drug addiction. Thorax 1995;50:1125-37.
124. Wu TC, Tashkin DP, Djaheb B, Rose JE. Pulmonary hazards of smoking marihuana as compared with tobacco. N Engl J Med 1998;31:347-51.
125. Mattes RD, Engelman K, Shaw LM, Elsohly MA. Cannabinoids and appetite stimulation. Pharmacol Biochem Behav 1994;49:187-95.
126. Busto U, Bendayan R, Sellers EM. Clinical pharmacokinetics of non-opiate abused drugs. Clin Pharmacokinet 1989;16:1-26.
127. Archer RA, Stark P, Lemberger I. Nabilone. In: Mechoulam R, editor. Cannabinoids as therapeutic agents. Boca Raton, FL: CRC Press; 1986, pp. 85-103.
128. Gray C. Cannabis: the therapeutic potential. Pharm J 1995;254:771-3.